11 results about "Membrane glycoproteins" patented technology

The invention relates to a novel three-antigen HSV-2 subunit vaccine as well as a preparation method and application thereof, and belongs to the technical field of biology. The novel three-antigen HSV-2 subunit vaccine comprises antigens and a composite adjuvant, the antigens comprise HSV-2 gB2 envelope glycoprotein, HSV-2 gC2 envelope glycoprotein and HSV-2 gD2 envelope glycoprotein, and the composite adjuvant is CpG oligonucleotide and an aluminum adjuvant; the vaccine provided by the invention can induce a high-level neutralizing antibody, and widens targets for developing a novel multi-target antigen HSV-2 virus vaccine.

The invention provides a chimeric envelope glycoprotein, a preparation method thereof and an envelope plasmid, a packaging method and a kit of the chimeric envelope glycoprotein, and particularly relates to a preparation method of the chimeric envelope glycoprotein, the chimeric envelope glycoprotein and a lentivirus envelope plasmid. The invention discloses a pseudotyped packaging method of lentivirus and a kit. The amino acid sequence of the wild type VSV-G envelope glycoprotein is chimeric with the amino acid sequences of other envelope glycoproteins, and compared with the initial wild type envelope glycoprotein, the obtained chimeric envelope glycoprotein can effectively improve the lentivirus packaging efficiency, biological activity and other properties.

The application provides a virus envelope chimeric receptor and related biomaterials and applications thereof, and belongs to the technical field of molecular biology. Specifically disclosed is a virus envelope chimeric receptor, which comprises, in sequence, an antibody or antigen-binding fragment thereof, a hinge region, a transmembrane region and an intracellular region; the hinge region is selected from a hinge region composed of a hinge region of a CD8 molecule and a hinge region of a vesicular stomatitis virus envelope glycoprotein; the transmembrane region of the virus envelope chimeric receptor is selected from a transmembrane region of the vesicular stomatitis virus envelope glycoprotein; and the intracellular region of the virus envelope chimeric receptor is selected from an intracellular region of the vesicular stomatitis virus envelope glycoprotein. The virus envelope chimeric receptor is used for virus targeting, can improve the infection ability of viruses, reduces the infection rate of viruses on non-T cells to less than 5%, provides a safety guarantee for in-vivo CAR-T preparation, and can be used for industrial production.

The invention discloses a lentiviral vector with efficient transduction capability on T cells and application of the lentiviral vector. The lentiviral vector comprises a nucleic acid sequence for coding recombinant virus envelope glycoprotein, and the recombinant virus envelope glycoprotein has the following structure from the N end to the C end in sequence; wherein the element A is a protein element of wild type virus envelope glycoprotein, the element B is an auxiliary protein element, the auxiliary protein element specifically recognizes cell membrane surface protein, and the element C is a transmembrane structural domain and is a peptide bond or a peptide chain connector. The lentivirus obtained by packaging the lentivirus vector containing the recombinant virus envelope glycoprotein can transduce T lymphocytes with higher efficiency, introduces an exogenous gene into the T lymphocytes, and can be used as a vector in the preparation process of CAR-T cells, so that the production efficiency of the CAR-T cells is improved, and the yield of the CAR-T cells is increased.

This invention provides a method for efficient multi-gene editing and CAR site-directed integration based on BaEV envelope glycoprotein truncated viral particles and its application in immune cell engineering. The invention provides an MLV-VLP system utilizing BaEV envelope glycoprotein truncated particles to achieve efficient CRISPR-Cas9 delivery without electroporation or the use of randomly integrating viruses. Combined with adeno-associated virus (AAV6) delivery of HDR templates, it enables efficient site-directed integration of CAR sequences at target sites (such as TRAC, PD1, and B2M) in primary human T cells and NK cells. The prepared CAR-T or CAR-NK cells exhibit excellent cell killing, proliferation, and low exhaustion characteristics in vitro, achieving 100% tumor clearance in an in vivo mouse model. It can simultaneously achieve multi-gene knockout with high efficiency, supporting large-scale allogeneic CAR-T and CAR-NK cell production.

The invention provides a chimeric envelope glycoprotein, a preparation method thereof and an envelope plasmid, a packaging method and a kit of the chimeric envelope glycoprotein, and particularly relates to a preparation method of the chimeric envelope glycoprotein, the chimeric envelope glycoprotein and a lentivirus envelope plasmid. The invention discloses a pseudotyped packaging method of lentivirus and a kit. The amino acid sequence of the wild type VSV-G envelope glycoprotein is chimeric with the amino acid sequences of other envelope glycoproteins, and compared with the initial wild type envelope glycoprotein, the obtained chimeric envelope glycoprotein can effectively improve the lentivirus packaging efficiency, biological activity and other properties.

The present disclosure reports that a calcium-dependent serine protease, complement component is (C1s) has been identified as a protease responsive for cleavage of exogenous polypeptides expressed in mammalian cell lines such as CHO cells. These CHO cell lines provide for increased yield of antigenically correct, uncleaved exogenous polypeptide as compared to unmodified CHO cells expressing the active C1s protease. C1s-deficient cell lines and methods for use of same for producing exogenous polypeptides, e.g., human immunodeficiency virus (HIV) envelope glycoprotein polypeptides, such as, gp120 or human Factor VIII are provided.

A chimeric antigen receptor (CAR) comprises an extracellular antigen-binding domain, which comprises a polypeptide that binds to oncostatin M receptor (OSMR), leukemia inhibitory factor receptor (LIFR), a heterodimer between transmembrane glycoprotein 130 (gp130) receptor and OSMR, and / or a heterodimer between gp130 receptor and LIFR.

The present invention provides polypeptides, and polypeptide dimers, comprising a modified flavivirus envelope E polypeptide, wherein the modified flavivirus envelope E polypeptide comprises i) a cysteine residue in a fusion loop epitope of ectodomain DII; and ii) a cysteine residue in ectodomain DI located in an N-terminal portion of the polypeptide, nucleic acids, vectors, host cells, and pharmaceutical compositions comprising the same, and methods of inducing an immune response in subjects by administering the pharmaceutical compositions of the invention.

The invention discloses a human antibody A023 for resisting Marburg virus and application of the human antibody A023. The nucleotide sequence of a heavy chain variable region of the Marburg virus disease resistant envelope glycoprotein MARV GP4 human antibody is shown as SEQ ID NO: 1, and the nucleotide sequence of a light chain variable region of the Marburg virus disease resistant envelope glycoprotein MARV GP4 human antibody is shown as SEQ ID NO: 2. The human antibody provided by the invention can be specifically recognized and combined with the MARV GP4, and can be used for diagnosis and treatment of the Marburg virus MARV GP4.

This invention belongs to the field of virology, specifically relating to a chimeric VSV recombinant virus and its applications; specifically, it discloses a chimeric VSV recombinant virus strain co-expressing NiV G and F proteins, wherein the chimeric VSV recombinant virus strain is rVSV△G / NiVMYGF and rVSV△G / NiVBDGF; based on its complete viral structure, higher immunogenicity and better safety, it can serve as an important viral reserve resource for the effective prevention and control, diagnosis and detection, vaccine preparation and antiviral treatment products of Nipah disease in the future.